CellaVision: First Comments on Q2
Redeye’s first comments on CellaVision’s report for Q2. The report showed sales slightly higher at SEK 118m vs our expectations of SEK 115m. However, the gross margin was a tad lower at 66% compared with the 68% expected. We still have a positive long-term view and believe that short-term dips can provide good opportunities to buy the share.